SAR342434, or Admelog, a follow-on of insulin lispro (Humalog), showed similar efficacy, safety, and immunogenicity to its reference in patients with type 2 diabetes who also used insulin glargine (Lantus) as basal insulin, according to the results of the SORELLA-2 study, published in the January 2018 issue of Diabetes Technology & Therapeutics.
SAR342434, or Admelog, a follow-on of insulin lispro (Humalog), showed similar efficacy, safety, and immunogenicity to its reference in patients with type 2 diabetes who also used insulin glargine (Lantus) as basal insulin, according to the results of the SORELLA-2 study, published in the January 2018 issue of Diabetes Technology & Therapeutics.
Karl-Michael Derwahl, MD, PhD, and colleagues conclude that Admelog and Humalog, when used for 6 months in combination with Lantus, provide effective and similar glucose control in patients with type 2 diabetes. Admelog is sponsored by Sanofi, which funded the study.
SORELLA-2 was a 6-month, randomized, open-label, multinational Phase 3 study in patients with diabetes who received multiple daily injections of Admelog (n = 253) or Humalog (n = 252) plus once-daily Lantus. Insulin doses were adjusted to achieve fasting and 2-hour postprandial glucose targets according to American Diabetes Association guidelines.
The study’s primary endpoint was the hemoglobin A1c (HbA1c) change from baseline to week 26; secondary endpoints included fasting plasma glucose (FPG), 7-point self-monitored plasma glucose (SMPG) profiles, hypoglycemic events, treatment emergent adverse events (TEAEs), and anti-insulin antibodies (AIA).
Researchers report the following:
The investigators note that, because the study population was largely adult white Caucasian patients with small numbers of black and Asian patients, caution should be taken when extending the results to other ethnic populations or subgroups.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.